ClinicalTrials.gg
TerminatedNCT03369587Updated Jul 28, 2023

Handwriting Interventions for People With Parkinson's

A Phase 2 interventional study of Handwriting Practice in Parkinson Disease, sponsored by Oxford Brookes University. Terminated at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Oxford Brookes University · Phase 2, Interventional, and Treatment

Why this study was terminated
Not feasible to restarted after Covid pandemic - analysis will be on data collected before study suspended
Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background: Problems with handwriting are frustrating and debilitating and affect the majority of people with Parkinson's. Manifest as micrographia it is a distinctive feature of the condition characterised by small handwriting and/or a progressive reduction in size through a sentence[2] coupled with a reduction in writing speed and legibility.

In Parkinson's impaired automaticity is thought to contribute to handwriting deficits and attention has been shown to improve both 'consistent' (small handwriting) and 'progressive' (progressive reduction in letter size through a sentence) aspects of the symptom. Moreover, recent interventional studies indicate handwriting may be improved through practice. This study is investigating a novel handwriting practice stimulus to improve symptoms of micrograpthia

Question: Is a diverging line cued handwriting intervention potentially more effective at improving symptoms of mircograpthia than a parallel line cued handwriting intervention in people with Parkinson's?

Specifically, an assessor blind randomised controlled exploratory trial will:

  1. Estatimate the effect of the intervention on measures of: Handwriting amplitude (consistent and progressive reduction), hand writing performance and percieved handwriting difficulties.
  2. Explore the appropriateness of these outcome measures
  3. Explore the approriateness of eligibilty criteria
  4. Explore intervention fidelity
  5. Explore participants views of the intervention

Design: A phase II exploratory randomised controlled trial of a handwriting intervention with an active comparator control group and blinded assessments

Setting: The intervention will be carried out at home

Sample size: This study is not designed to determine efficacy. The aim to recruit a total of 50 people (25 people per group) in order to estimate the effects on outcome measures and achieve the aims of this exploratory trial.

Assessment: Participants will be asked to follow their usual Parkinson's medication regime and if they have ON and OFF periods, assessments will be carried out during ON state.

Duration and follow-up: the assessment is schedule 0Weeks (baseline), 6weeks (end intervention) and 12weeks (follow up). Assessments will be carried out by a researcher blind to trial arm allocation using all outcome measures.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Handwriting, Micrographia
03

In context

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,097 are open to participants now.

This study's enrollment of 48 is above the median of 40 across 3,365 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Oxford Brookes University is the lead sponsor of 35 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years old
  • Diagnosis of idiopathic Parkinson's disease
  • A score of ≤3 on the Hoehn and Yahr scale
  • Self-reported problem with handwriting (≥1 UPDRSII, 2.7)
  • Able to communicate in Italian
  • Following a stable medication regimen (no changes in the last 2 weeks and anticipated changes for the course of the study).

Exclusion criteria

Exclusion Criteria:

  • Severe depression or psychosis (history of),
  • reduced cognition that would preclude active involvement or capacity to consent (according to stages outlined in metal capacity act (ie trigger, information, existing diagnosis, functional test))
  • Orthopaedic, neurological or other condition that significantly impairs hand function,
  • Pregnancy
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Diverging lines

    What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of diverging lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.

    Behavioral: Handwriting Practice

  • Active comparator
    Parallel lines

    What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of parallel lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.

    Behavioral: Handwriting Practice

Interventions

  • BehavioralHandwriting Practice

    Self-directed home handwriting practice daily for 6 weeks

06

What researchers measure

Primary outcomes

  1. Micrograpthia: Area of 'el' 8 character text sequence writing task

    Area (maximum height x maximum width) of handwritten cursive 'elelelel' character sequence measured to the nearest of 0.5mm

    Time frame: 6 weeks

  2. Self-reported problem with handwriting: Item 2.7 on the Movement Disorders Society Unified Parkinson's Rating Scale

    A scale from 0-4 (0: normal: no problems, 4: severe: most or all words cannot be read) asking 'Over the past week, have people usually had trouble reading your handwriting?'

    Time frame: 6 weeks

  3. Writing speed: Time taken to write an Italian proverb

    Time taken to the nearest 10th second to hand write the sentence (written across one line): 'Chi lascia la via vecchia per la nuova, sa quello che lascia ma non sa quello che trova'

    Time frame: 6 weeks

  4. Writing amplitude: Area of the both 'lascia' contained in an Italian proverb

    Area (maximum height x maximum width) of 'lascia' contained in handwritten sentence: 'Chi lascia la via vecchia per la nuova, sa quello che lascia ma non sa quello che trova'. Measured to the nearest 0.5mm

    Time frame: 6 weeks

Secondary outcomes

  1. Micrograpthia under cognative motor interference: Area of 'el' 8 character text sequence writing task

    Area (maximum height x maximum width) of handwritten cursive 'elelelel' character sequence performed concurrently with cognative task (serial 3 subtraction). Measured to the nearest of 0.5mm

    Time frame: 6 weeks

  2. Micrograpthia under cognative motor interference: Area of 'el' 8 character text sequence writing task

    Area (maximum height x maximum width) of handwritten cursive 'elelelel' character sequence performed concurrently with cognative task (serial 3 subtraction). Measured to the nearest of 0.5mm

    Time frame: 12 weeks

  3. Legibility of Free writing

    Ratio between total number of words written and total number of legible words written during a 5 minutes of free writing task: A reflection on the day

    Time frame: 6 weeks

  4. Legibility of Free writing

    Ratio between total number of words written and total number of legible words written during a 5 minutes of free writing task: A reflection on the day

    Time frame: 12 weeks

  5. EQ-5D-5L

    Standardized Instrument to measure health outcome

    Time frame: 6 weeks

  6. EQ-5D-5L

    Standardized Instrument to measure health outcome

    Time frame: 12 weeks

  7. Micrograpthia: Area of 'el' 8 character text sequence writing task

    Area (maximum height x maximum width) of handwritten cursive 'elelelel' character

    Time frame: 12 weeks

  8. Self-reported problem with handwriting: Item 2.7 on the Movement Disorders Society

    0-4 scale (0: normal: no problems, 4: severe: most or all words cannot be read) asking 'Over the past week, have people usually had trouble reading your handwriting?'

    Time frame: 12 weeks

  9. Writing speed: Time taken to write an Italian proverb

    Time taken to the nearest 10th second to hand write the sentence (written across one line): 'Chi lascia la via vecchia per la nuova, sa quello che lascia ma non sa quello che trova'

    Time frame: 12 weeks

  10. Writing amplitude: Area of the both 'lascia' contained in an Italian proverb

    Area (maximum height x maximum width) of 'lascia' contained in handwritten sentence: 'Chi lascia la via vecchia per la nuova, sa quello che lascia ma non sa quello che trova'. Measured to the nearest 0.5mm

    Time frame: 12 weeks

07

Study locations

1 site
  • European Parkinson's therapy centre
    Darfo Boario Terme, Brescia 25041, Italy
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03369587
Lead sponsor
Oxford Brookes University
Collaborators
European Parkinson's Therapy Centre
Responsible party
Dr Johnny Collett (Senior Research Fellow, Oxford Brookes University) — Principal investigator
First posted
Dec 12, 2017
Start date
Nov 2, 2017
Primary completion
Feb 28, 2020
Completion
Apr 21, 2022
Last update
Jul 28, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion